Luca Vago

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9215033/publications.pdf

Version: 2024-02-01

67 papers	4,535 citations	126858 33 h-index	106281 65 g-index
69 all docs	69 docs citations	69 times ranked	5278 citing authors

#	Article	IF	Citations
1	Mother Donors Improve Outcomes after HLA Haploidentical Transplantation: A Study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation. Transplantation and Cellular Therapy, 2022, 28, 206.e1-206.e6.	0.6	2
2	CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Science Translational Medicine, 2022, 14, eabg8027.	5.8	21
3	Allogeneic hematopoietic stem cell transplantation in patients older than 65 years with acute myeloid leukemia and myelodysplastic syndrome: a 15-year experience. Bone Marrow Transplantation, 2022, 57, 678-680.	1.3	4
4	Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse. Cancer Discovery, 2022, 12, 1449-1461.	7.7	26
5	Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. Therapeutic Advances in Hematology, 2022, 13, 204062072210908.	1.1	3
6	Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia. Leukemia, 2021, 35, 585-594.	3.3	18
7	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. Transplantation and Cellular Therapy, 2021, 27, 406.e1-406.e11.	0.6	4
8	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 1900-1907.	1.3	18
9	Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity, 2021, 54, 737-752.e10.	6.6	58
10	Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood, 2021, 138, 2655-2669.	0.6	43
11	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. Transplantation and Cellular Therapy, 2021, 27, 776.e1-776.e13.	0.6	26
12	Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type. Current Research in Translational Medicine, 2021, 69, 103313.	1.2	0
13	Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study. Haematologica, 2021, 106, 1480-1483.	1.7	5
14	Therapy-Induced Senescence As an Anti-Cancer and Immune-Stimulatory Strategy. Blood, 2021, 138, 4419-4419.	0.6	1
15	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation. Haematologica, 2020, 105, e186-e189.	1.7	12
16	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 147.	2.2	39
17	Immune escape and immunotherapy of acute myeloid leukemia. Journal of Clinical Investigation, 2020, 130, 1552-1564.	3.9	160
18	Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. Frontiers in Cell and Developmental Biology, 2019, 7, 207.	1.8	32

#	Article	IF	Citations
19	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	5.8	120
20	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	15.2	253
21	Clonal evolution and immune evasion in posttransplantation relapses. Hematology American Society of Hematology Education Program, 2019, 2019, 610-616.	0.9	15
22	Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood, 2019, 133, 1290-1297.	0.6	100
23	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	1.3	8
24	Mechanisms of Immune Resistance. , 2019, , 457-460.		0
25	Nanosphere's VerigeneÂ® Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance. Clinical Hematology International, 2019, 1, 120-123.	0.7	2
26	Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1379-1389.	1.3	85
27	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	1.3	10
28	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	15.2	216
29	Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients. Bone Marrow Transplantation, 2018, 53, 410-416.	1.3	10
30	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood, 2018, 131, 247-262.	0.6	164
31	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American Journal of Hematology, 2017, 92, 1011-1019.	2.0	14
32	Choosing the Alternative. Biology of Blood and Marrow Transplantation, 2017, 23, 1813-1814.	2.0	18
33	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. Blood, 2017, 130, 606-618.	0.6	71
34	A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT. Blood, 2017, 130, 1270-1273.	0.6	31
35	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Frontiers in Immunology, 2017, 8, 1444.	2.2	62
36	Elderly patientsâ€‰>â€‰65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. American Journal of Hematology, 2016, 91, E302-3.	2.0	2

#	Article	IF	Citations
37	Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica, 2016, 101, e157-e161.	1.7	55
38	Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2016, 51, 1022-1024.	1.3	6
39	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. Biology of Blood and Marrow Transplantation, 2016, 22, 2250-2255.	2.0	36
40	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. Blood, 2016, 128, 1979-1986.	0.6	66
41	Integrating a prospective pilot trial and patient-derived xenografts to trace metabolic changes associated with acute myeloid leukemia. Journal of Hematology and Oncology, 2016, 9, 115.	6.9	4
42	Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplantation, 2016, 51, 466-469.	1.3	6
43	High rate of hematological responses to sorafenib in <scp>FLT</scp>3â€<scp>ITD</scp> acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. European Journal of Haematology, 2016, 96, 629-636.	1.1	35
44	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. Blood, 2015, 125, 2865-2874.	0.6	119
45	Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology, 2015, 6, 95.	1.6	102
46	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2015, 21, 1506-1514.	2.0	121
47	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. Science Translational Medicine, 2015, 7, 317ra198.	5.8	102
48	Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia, 2015, 29, 396-405.	3.3	114
49	The Impact of Amino Acid Variability on Alloreactivity Defines a Functional Distance Predictive of Permissive HLA-DPB1 Mismatches in Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 233-241.	2.0	95
50	Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia, 2015, 29, 1143-1152.	3.3	110
51	Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall. Bone Marrow Transplantation, 2015, 50, 1262-1264.	1.3	11
52	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. Annals of Neurology, 2014, 75, 447-453.	2.8	43
53	Expertsâ€™ considerations on <scp>HLA</scp>â€haploidentical stem cell transplantation. European Journal of Haematology, 2014, 93, 187-197.	1.1	24
54	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Current Opinion in Hematology, 2012, 19, 427-433.	1.2	30

#	Article	IF	Citations
55	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. Blood, 2012, 120, 1820-1830.	0.6	47
56	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. Blood, 2012, 119, 4813-4815.	0.6	42
57	Genomic Loss of Mismatched Human Leukocyte Antigen and Leukemia Immune Escape From Haploidentical Graft-Versus-Leukemia. Seminars in Oncology, 2012, 39, 707-715.	0.8	51
58	Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3. Journal of Immunology, 2012, 189, 1418-1430.	0.4	76
59	Significantly higher frequencies of alloreactive CD4+ T cells responding to nonpermissive than to permissive HLA-DPB1 T-cell epitope disparities. Blood, 2010, 116, 1991-1992.	0.6	24
60	KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. Journal of Experimental Medicine, 2009, 206, 2557-2572.	4.2	211
61	Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes. Experimental Hematology, 2009, 37, 616-628.e2.	0.2	121
62	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. New England Journal of Medicine, 2009, 361, 478-488.	13.9	459
63	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase Iâ€“II study. Lancet Oncology, The, 2009, 10, 489-500.	5.1	458
64	Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood, 2009, 114, 1437-1444.	0.6	131
65	Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors. Leukemia, 2008, 22, 2119-2122.	3.3	12
66	Temporal, quantitative, and functional characteristics of single-KIRâ€“positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood, 2008, 112, 3488-3499.	0.6	113
67	Frequency and Targeted Detection of HLA-DPB1 T Cell Epitope Disparities Relevant in Unrelated Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 1031-1040.	2.0	50